ABL Bio Inc.
Weon-Kyoo You is an accomplished researcher and executive in the biopharmaceutical industry with extensive experience in cancer therapeutic development. Currently serving as the R&D Head and Executive Vice President at ABL Bio, Inc. since March 2016, Weon-Kyoo has previously held positions including Principal Research Scientist at Hanwha Chemical Bio R&D Center and Senior Research Scientist at BioBud. Throughout the career, Weon-Kyoo has led projects that resulted in multiple patented innovations and significant advancements in therapeutic antibody development, including nonclinical studies and large-scale production processes. With a strong educational background, including a PhD in Biochemistry from Yonsei University, Weon-Kyoo has contributed to numerous publications and played key roles in multiple research endeavors across prestigious institutions and companies.
This person is not in any teams
ABL Bio Inc.
ABL Bio Inc. (Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com